The Psoriatic Arthritis market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Psoriatic Arthritis: An Overview
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary greatly between patients. It can present with oligoarticular joint involvement that is typically asymmetric or as a polyarticular disease affecting five or more joints, usually with an asymmetric distribution similar to that of rheumatoid arthritis.
Psoriatic arthritis patients require input from the multidisciplinary rheumatology team consisting of physiotherapists, occupational therapists, podiatrists, and other healthcare professionals. There is no curative option, treatment is usually focused on a particular goal, with minimal disease activity (MDA) criteria recommended as the treatment target in patients with Psoriatic Arthritis.
Psoriatic Arthritis Market Key Facts
According to the National Psoriatic Foundation, about 1 in 3 people or 30% with psoriasis develop psoriatic arthritis (PsA) – as many as 2.4 million Americans – and PsA can develop at any age.
According to a retrospective study of German healthcare insurance data, Psoriatic Arthritis had prevalence rates of 0.3% respectively, in 2016 (Grellmann et al., 2020)
As per the estimates by DelveInsight, there is no gender-based difference but the prevalence of severe cases is the highest followed by moderate and mild.
According to study by Pérez et., al (2020), the prevalence of Psoriatic Arthritis in Spain was among the highest reported to date, only below that reported in Norway (0.67%) and slightly higher than that reported in Italy (0.42%).
Psoriatic Arthritis market size is expected to increase during the forecast period owing to the launch of Biosimilars and Biologics as well as the rise in prevalence and expedite R&D.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Psoriatic Arthritis market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Psoriatic Arthritis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Psoriatic Arthritis Epidemiology
The epidemiology section covers insights about the historical and current Psoriatic Arthritis patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Psoriatic Arthritis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Psoriatic Arthritis market or expected to get launched in the market during the study period. The analysis covers Psoriatic Arthritis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Psoriatic Arthritis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/psoriatic-arthritis-market
Psoriatic Arthritis Therapeutics Analysis
Psoriatic Arthritis companies:
And many others.
Psoriatic Arthritis therapies covered in the report include:
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/psoriatic-arthritis-market
Table of Content
1. Key Insights
2. Executive Summary
3. Psoriatic Arthritis Competitive Intelligence Analysis
4. Psoriatic Arthritis Market Overview at a Glance
5. Psoriatic Arthritis Disease Background and Overview
6. Psoriatic Arthritis Patient Journey
7. Psoriatic Arthritis Epidemiology and Patient Population
8. Psoriatic Arthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Psoriatic Arthritis Unmet Needs
10. Key Endpoints of Psoriatic Arthritis Treatment
11. Psoriatic Arthritis Marketed Products
12. Psoriatic Arthritis Emerging Therapies
13. Psoriatic Arthritis Seven Major Market Analysis
14. Attribute Analysis
15. Psoriatic Arthritis Market Outlook (7 major markets)
16. Psoriatic Arthritis Access and Reimbursement Overview
17. KOL Views on the Psoriatic Arthritis Market.
18. Psoriatic Arthritis Market Drivers
19. Psoriatic Arthritis Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/psoriatic-arthritis-market
Other Latest Healthcare Reports By DelveInsight
DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States